| Literature DB >> 20468059 |
Thomas I Konneker1, James J Crowley, Corey R Quackenbush, Richard S E Keefe, Diana O Perkins, T Scott Stroup, Jeffrey A Lieberman, Edwin van den Oord, Patrick F Sullivan.
Abstract
A promoter polymorphism in the serotonin transporter gene has been widely studied in neuropsychiatry. We genotyped the 5-HTTLPR/rs25531 triallelic polymorphism in 728 schizophrenia cases from the CATIE study and 724 control subjects. In a logistic regression with case/control status as dependent variable and 7 ancestry-informative principal components as covariates, the effect of 5-HTTLPR/rs25531 composite genotype was not significant (odds ratio = 1.008, 95% CI 0.868-1.172, P = 0.91). In cases only, 5-HTTLPR/rs25531 was not associated with neurocognition (summary neurocognitive index P = 0.21, working memory P = 0.32) or symptomatology (PANSS positive P = 0.67 and negative symptoms P = 0.46). We were unable to identify association of the triallelic 5-HTTLPR with schizophrenia, neurocognition, or core psychotic symptoms even at levels of significance unadjusted for multiple comparisons. (c) 2010 Wiley-Liss, Inc.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20468059 PMCID： PMC3181051 DOI： 10.1002/ajmg.b.31077
Source DB: PubMed Journal: Am J Med Genet B Neuropsychiatr Genet ISSN： 1552-4841 Impact factor: 3.568